28 results about "Azacitidine" patented technology

The invention relates to the field of anti-tumor drugs, and discloses an anti-diffuse large B-cell lymphoma pharmaceutical composition, a preparation method and application thereof, the composition comprises azacitidine and Sanilisoma, the composition can improve the accumulation amount of VDUP1 protein in a cell nucleus through the combination of the methylation effect of DNMT3b on VDUP1 protein and the inhibition of XPO1 activity by Sanilisoma, and the anti-diffuse large B-cell lymphoma pharmaceutical composition can be used for preparing anti-diffuse large B-cell lymphoma. The chemotherapy effect is remarkably improved, the sensitivity of the DLBCL to the Sanisole is remarkably improved, and particularly, the pharmaceutical composition has a remarkable curative effect on R / R DLBCL patients.

The invention discloses a combined treatment medicine for acute myelogenous leukemia. The combined treatment medicine is prepared from vinaclaria, azacitidine and aclarithromycin. The medicine is applied to preparation of an acute myelogenous leukemia cell proliferation inhibitor; the medicine is applied to preparation of an acute myelogenous leukemia cell apoptosis inducer. The three medicines are combined to achieve a synergistic effect: the three medicines have a synergistic anti-tumor effect instead of a simple superposition effect, and a new combined medication mechanism is a result obtained through laboratory research and an initial effect of clinical application. The subsequent consolidation treatment scheme may also be used for part of initially treated patients with acute myelogenous leukemia, which are not suitable for enhanced chemotherapy or intense intense treatment by using targeted drugs, and relapse / refractory patients with acute myelogenous leukemia, and a better treatment scheme can also bring new hope and dawn to more patients.

The present disclosure relates generally to pharmaceutical dosage forms comprising azacitidine and chidaridine.

The present invention provides a composition comprising a cytidine analog, in particular decitabine or azacitidine. In particular, the present invention provides a composition comprising a cytidine analog, in particular decitabine or azacitidine, which is useful for topical application. The present invention also provides the use of such compositions for medical conditions in the keratinizing and non-keratinizing epithelium / skin, such as the treatment of human papillomavirus (HPV)-related pre-cancerous conditions.

Provided are methods for treating hematologic malignancy, especially AML-MRC, MDS and / or MM. Specifically, provided are methods for treating AML-MRC and MDS with a compound of formula (I) or a pharmaceutically acceptable salt thereof, optionally in combination with at least one additional anti-cancer agent such as 5-azacitidine or cytarabine, and treating MM with a compound of formula (I) or a pharmaceutically acceptable salt thereof, optionally in combination with at least one additional anti-cancer agent such as pomalidomide, thalidomide, lenalidomide, and / or dexamethasone.

The application discloses application of DNA methyltransferase inhibitors in preparation of drugs for treating polycystic kidney disease. Preferably, the DNA methyltransferase inhibitor is decitabine or azacitidine, and the polycystic kidney disease is polycystic kidney disease caused or aggravated by mTOR activation. The application uses Tsc2 knockout mouse embryo fibroblasts MEF and Tsc2 kidney-specific knockout mice, finds that after treatment of the DNA methyltransferase inhibitor decitabine, cell proliferation is inhibited, polycystic kidney disease of the mice is relieved, and kidney function is partially recovered. The application provides a new and effective technical means for treatment of polycystic kidney disease.

The present disclosure relates to a CD47-SIRPα blocking agent of formula (I) stereoisomers thereof, and pharmaceutically acceptable salts, solvates, amides and esters of the compound of formula (I) and stereoisomer thereof and Azacitidine for use in combination with Azacitidine in a method of treating or delaying progression of a disease or a disorder mediated by CD47-SIRPα pathway in a human subject suffering from said disease, such as hematological cancer.

The invention provides a combined pharmaceutical composition of a CDK8 / 19 inhibitor and azacitidine and application of the combined pharmaceutical composition in preparation of antitumor drugs. Particularly, the compound shown in the formula (B) and azacitidine are combined for use, so that a relatively good synergistic effect is shown in a cell proliferation inhibition experiment and an in-vivo tumor model. # imgabs0 #

A pharmaceutical composition comprising i) a recombinant fusion protein that comprises a mutated SIRPαD1 and a functional IgG1 heavy chain constant region, and ii) azacitidine, for use in treating chronic myelomonocytic leukemia or myelodysplastic syndrome in a subject in need thereof.

The disclosure describes T cells that express chimeric antigen receptors (CARs), as well as pharmaceutical compositions comprising T cells and methods of making and using such T cells. Particularly, this disclosure describes T cells expressing a CAR that binds to CD64, and methods of use in treating acute myeloid leukemia.

Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).

The present invention relates to a therapeutic combination of a BTN3A-activating antibody, a Bcl-2 family inhibitor and a demethylating agent, which is useful, inter alia, in the treatment of cancer, in particular hematological malignancies. The present disclosure more particularly relates to the combined use of BTN3A-activating antibodies that activate the cytolytic function of V [gamma] 9V [delta] 2T cells, WiNtural that selectively inhibits the Bcl2 receptor, and a demethylating agent, such as azacitidine, to synergistically and specifically promote the anti-cancer activity of V [gamma] 9V [delta] 2T cells.

Provided herein are methods of treating acute myeloid leukemia (AML) in a subject in need thereof, comprising administering to the subject combinations of Compound 1, or a pharmaceutically acceptable salt thereof, venetoclax, and 5-azacitidine. Also provided herein are methods of inhibiting / overcoming resistance of AML to venetoclax in a subject in need thereof, and / or improving the efficacy of venetoclax in the treatment of AML in a subject in need thereof, comprising administering to the subject combinations of Compound 1, or a pharmaceutically acceptable salt thereof, venetoclax, and 5-azacitidine.

The present invention provides a compound of Formula (I), or a salt thereof : (I) for use in the treatment or prophylaxis of a cancer, wherein the compound of Formula (I) is administered in combination with Azacitidine and Venetoclax wherein the three compounds are administered simultaneously, sequentially or separately.

The present invention provides a method of treatment and composition for CDC7 inhibitor combinational therapy for treatment of proliferative diseases. In an embodiment, the composition of the present invention comprises a therapeutically effective amount of a combination of a CDC7 inhibitor of the present invention or a pharmaceutically acceptable salt thereof and one or more antineoplastic agents. In an embodiment, the CFC7 inhibitor comprises granaticin B. In an embodiment, the antneoplastic agent comprises azacitidine and venetoclax. The present invention further provides a method of treatment comprising the step of administration to a subject suffering from proliferative disease of any embodiment of the composition of the present invention.

The present invention discloses an experimental box for azacitidine, a raw material drug, and relates to the technical field of experimental equipment. The box comprises a box body and a sealing device, wherein a temperature control device is fixedly installed on the left side of the box body, a button is fixedly installed on the left side of the temperature control device, and the button is electrically connected to the temperature control device. A replacement hole is opened on the front side of the box body, a replacement plate is slidably installed on the front side of the box body, and a sealing plate is slidably penetrated on the right side of the box body, wherein the sealing device comprises a limiting hole, a limiting rod, a limiting spring, a U-shaped rod, a T-shaped plate, a stabilizing plate and a mesh frame. After an experimental container containing azacitidine is placed in the box body, the sealing plate is manually pulled to move to the left to reset and restore the sealing of the box body. Loosening of the sealing plate will cause moisture in the air to enter the box body, thereby accelerating the degradation of azacitidine. The anti-mistouch restriction of the T-shaped plate can ensure that the sealing plate is always tightly closed, thereby ensuring the stability of azacitidine.

The invention provides a light-triggered epigenetic reprogramming engineering microorganism with a CT (Computed Tomography) imaging function as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The engineering microbial strain provided by the invention is prepared by coupling Mo1.33C nanosheets and azacitidine independently or jointly as active pharmaceutical ingredients and facultative anaerobic escherichia coli capable of realizing precise delivery of tumor sites as a carrier. An effective delivery platform of a DNMT1 inhibitor and / or iMxene is established, epigenetic immunity is activated, a way is laid for epigenetic regulation in solid tumor treatment, meanwhile, Mo1. 33C is a reagent for CT imaging and infrared imaging and can be used for multi-mode diagnosis and PTT and epigenetic treatment, and an integrated diagnosis and treatment nano platform is created.

A method of treating chronic myelomonocytic leukemia or myelodysplastic syndrome in a subject in need thereof, comprising the steps of: (a) administering intravenously to the subject for the chronic myelomonocytic leukemia about 2.0 mg / kg body weight per day of a recombinant fusion protein of SEQ ID NO: 1 in the form of a composition comprising a pharmaceutically acceptable excipient and the recombinant fusion protein, (b) about 65 minutes to about 75 minutes after completing the administering of step (a), administering subcutaneously to the subject about 75 mg / m2 of azacitidine, and (c) after steps (a) and (b), repeating step (a) once weekly, and administering subcutaneously to the subject about 75 mg / m2 of azacitidine once daily, wherein on the days that the subject is also having step (a) repeated, the azacitidine is administered about 65 minutes to about 75 minutes after completing the repeated administering of step (a).

The present disclosure relates to a CD47-SIRPα blocking agent of formula (I) stereoisomers thereof, and pharmaceutically acceptable salts, solvates, amides and esters of the compound of formula (I) and stereoisomer thereof and Azacitidine for use in combination with Azacitidine in a method of treating or delaying progression of a disease or a disorder mediated by CD47-SIRPα pathway in a human subject suffering from said disease, such as hematological cancer.

The presented invention relates to Azacitidine (compound of formula (1)) particles characterized by bimodal particle size distribution, process for preparation thereof and composition comprising them.

The present disclosure relates generally to pharmaceutical dosage forms comprising azacitidine and cedazuridine.

The present disclosure relates generally to pharmaceutical dosage forms comprising azacitidine and cedazuridine.

The invention belongs to the technical field of medicinal preparations of antiviral drugs, and particularly relates to freeze-dried powder containing azacitidine gold nano-liposomes, application and a process. The freeze-dried powder contains the following components in parts by weight: 10 parts of azacitidine gold nano-liposome and 20-36 parts of a protective agent, the azacitidine gold nano-liposome is prepared from the following raw materials in parts by weight: 5 to 10 parts of carboxylated-azacitidine, 10 to 20 parts of PEG (Polyethylene Glycol)-gold nanoparticles, 15 to 35 parts of hydrogenated soybean phospholipid, 2 to 7 parts of taraxasterol and 5 to 11 parts of distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000. By optimizing the formula, the drug encapsulation efficiency and the drug loading capacity can be guaranteed at the same time, the finally prepared freeze-dried powder has high stability, and in rat experiments, the drug has a lasting effect and can effectively reduce the tumor volume and prolong the survival days.

The present disclosure relates generally to pharmaceutical dosage forms comprising azacitidine and cedazuridine.

The application relates to the field of medicine synthesis, in particular to a refining method of azacitidine. Crude azacitidine is added into a refining solvent to be stirred and dissolved, a crystallization solvent is added dropwise to be stirred, after crystals are separated out, temperature is reduced to be stirred to separate out crystals, and then filtration is carried out; the filter cake is washed with the crystallization solvent, and high-purity single crystal azacitidine is obtained; the refining solvents used in the application are low-toxicity solvents, the operation is simple and safe, and the problem of excessive residue is avoided; the crystallization solvents are low-boiling-point solvents, which are beneficial to recycling and utilization of the crystallization solvents and cost saving. Finally, single crystal products are obtained, the problem caused by different crystal types is avoided, the yield is improved, the operation is simplified, and the method is suitable for industrial production.

Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.

Pharmaceutical compositions comprising oil as a vehicle, a suspending agent, and a surfactant are disclosed to be used in conjunction with active pharmaceutical ingredients which are water soluble or insoluble, or which are sensitive to water but insoluble in oil. Such active pharmaceutical ingredients may include temozolomide, lenalidomide, Oxaliplatin, Cisplatin, Carboplatin, 5-fluorouracil, irinotecan, topotecan, cyclophosphamide, doxorubicin, vincristine, vinblastine, Melphalan, Chlorambucil, Dacarbazine, Daunorubicin, Epirubicin, Mitoxantrone, Etoposide, Teniposide, Azacitidine, Cytarabine, Gemcitabine, vinoralbine, Pemetrexed, a derivative thereof, or a combination thereof. The pharmaceutical compositions may be administered as an oral suspension. Other embodiments are directed towards methods of using and methods of making such formulations.